CentryMed (Drug Discovery) Overview
- Year Founded
-
2017
- Status
-
IPO Registration
- Employees
-
47
- Latest Deal Type
-
IPO
- (Announced)
- Financing Rounds
-
10
CentryMed (Drug Discovery) General Information
Description
Developer of antibody-based therapeutic drugs designed for targeted treatment of malignant tumors and autoimmune diseases. The company's technology utilizes four generations of platforms, including multi-channel antibody discovery, H-form bispecific T-cell engagers, protease-activated bispecific T-cell engagers, and multifunctional logic-gated T-cell engagers, providing pharmaceutical researchers with monoclonal and bispecific antibodies, enabling the development of targeted therapies for complex diseases with improved efficacy and safety profiles.
Contact Information
Website
www.centrymed.comCorporate Office
- Room 2008, 20th Floor, Huachuang Building
- Number 511 Jianye Road, Changhe Street, Binjiang District
- Hangzhou, Zhejiang 310051
- China
Corporate Office
- Room 2008, 20th Floor, Huachuang Building
- Number 511 Jianye Road, Changhe Street, Binjiang District
- Hangzhou, Zhejiang 310051
- China
CentryMed (Drug Discovery) Timeline
CentryMed (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CentryMed (Drug Discovery) Patents
CentryMed (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025035356-A1 | Antibodies against dll3 and uses thereof | Inactive | 14-Aug-2023 | ||
| WO-2025010538-A1 | Antibodies against gucy2c and uses thereof | Inactive | 07-Jul-2023 | ||
| WO-2024254778-A1 | Antibodies against cll1 and uses thereof | Inactive | 14-Jun-2023 | ||
| WO-2024254757-A1 | Bispecific antibodies against folr1 and uses thereof | Inactive | 13-Jun-2023 | ||
| WO-2024168588-A1 | Egfr and lag3 dual targeted bispecific antibody and uses thereof | Inactive | 15-Feb-2023 | A61P35/00 |
CentryMed (Drug Discovery) Signals
CentryMed (Drug Discovery) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CentryMed (Drug Discovery) FAQs
-
When was CentryMed (Drug Discovery) founded?
CentryMed (Drug Discovery) was founded in 2017.
-
Where is CentryMed (Drug Discovery) headquartered?
CentryMed (Drug Discovery) is headquartered in Hangzhou, China.
-
What is the size of CentryMed (Drug Discovery)?
CentryMed (Drug Discovery) has 47 total employees.
-
What industry is CentryMed (Drug Discovery) in?
CentryMed (Drug Discovery)’s primary industry is Drug Discovery.
-
Is CentryMed (Drug Discovery) a private or public company?
CentryMed (Drug Discovery) is a Private company.
-
What is CentryMed (Drug Discovery)’s current revenue?
The current revenue for CentryMed (Drug Discovery) is .
-
How much funding has CentryMed (Drug Discovery) raised over time?
CentryMed (Drug Discovery) has raised $81.6M.
-
Who are CentryMed (Drug Discovery)’s investors?
Shenzhen GTJA Investment Group, Hainan Xinguoxing Private Equity Fund Management, Hangzhou Bejia Investment Management, Hangzhou Hi-Tech Financial Investment Group, and Hangzhou Tailong Venture Capital Partnership are 5 of 13 investors who have invested in CentryMed (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process